Table 3 Overview of cancer vaccine platforms
From: Vaccines: a promising therapy for myelodysplastic syndrome
Vaccine type | Merits | Drawbacks | Tested MDS vaccines |
|---|---|---|---|
Peptide-based vaccine | Low toxicity Easy production and low cost | Low immunogenicity Short peptides are HLA-restricted | WT4869 DSP-7888 PR-1 vaccine NY-ESO-1 vaccine |
Cell-based vaccine: 1. Whole-cell vaccine 2. Dendritic cell vaccine | Broader target population DCs are potent APCs | Nonspecific targets Potential release of immunosuppressive factors Cumbersome manufacturing process and high cost Immature DCs can induce tolerance | GVAX DCP-001 |
Nucleic acid-based vaccine (DNA and mRNA) | Easy production Encode multiple antigens No HLA restriction | Require delivery systems Difficult handling and storage | Not tested |